HAPLN1 and Miyoshi myopathy: HAPLN1-PTR1 can reduce the MM cell toxicity of both bortezomib and ixazomib, but not carfilzomib, indicating that the latter drug can escape the resistance impact of HAPLN1-PTR1 despite its inability to inhibit NF-κB activation.